Table of Contents Table of Contents
Previous Page  319 / 812 Next Page
Information
Show Menu
Previous Page 319 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

S315

Objectives

Olfactory identification deficits are well described in

schizophrenia while the results for pleasantness ratings remain

unclear.

Aims

Evaluation of odor identification and hedonic judgment

related to severity of negative symptoms and -endorphin con-

centration.

Methods

Fifty outpatients with schizophrenia were included in

the study: 25 with negative symptoms (PN) and 25 without pre-

dominant negative symptoms (P). They were compared with 23

healthy individuals. In all study groups University of Pennsylva-

nia Smell Identification Test (UPSIT) and odor hedonic evaluation

were performed. Clinical symptoms severity was evaluated using

PANSS. Plasma concentrations of -endorphin were assayed in all

participants.

Results

PN made more odor identification errors than controls

(

P

= 0.000) and

P

sample (

P

= 0.001). Hedonic judgments of unpleas-

ant odors were significantly more pleasant in PN sample than in P

(

P

= 0.03) and controls (

P

= 0.041). PN had significantly higher con-

centration of -endorphin than

P

sample (

P

= 0.014) and controls

(

P

= 0.009). No relationship between -endorphin concentration

and odors identification and odor hedonic judgment was found in

both patient samples and controls.

Conclusions

Increased level of -endorphin is related to pre-

dominance of negative symptoms but probably it is not involved

in olfactory identification performance and hedonic judgment

in schizophrenia. Patients with predominant negative symptoms

revealed different pattern of pleasantness rating – they experience

unpleasant odors as more pleasant. Alterations in smell identifi-

cation and hedonic judgment could be differentially expressed in

some subtypes of schizophrenia.

Disclosure of interest

The author has not supplied his/her decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.684

EW567

Assessment of suicide risk in

schizophrenia with addictive

comorbidity

D. Vasile

, O. Vasiliu , D.G. Vasiliu , F. Vasile

Central University and Emergency Military Hospital “Dr. Carol

Davila”, Psychiatry, Bucharest, Romania

Corresponding author.

Introduction

Comorbid drug use disorders are associated with

greater risk for relapse in schizophrenia and lower adherence

to treatment. A comprehensive evaluation of patients with dual

diagnosis should address the problem of suicide risk, which is a

reputated complication of both psychotic disorders and drug use

disorders.

Objectives

Depression and suicide risk assessment in subjects

diagnosed with schizophrenia and drug related disorders.

Aims

To establish a protocol for early intervention in cases with

depressive features that associate suicide risk.

Methods

All the patients (

n

= 37, female

n

= 15, male

n

= 12) with

both schizophrenia and a drug related disorder, consecutively

admitted in our department during a 6-month period, were eval-

uated using Calgary Depression Scale for Schizophrenia (CDSS),

Positive and Negative Syndrome Scale (PANSS), Inventory of Drug

Taking Situations (IDTS), Clinical Global Impression- Severity (CGI-

S). Subjects were evaluated at admission, discharge and after 3

months.

Results

A percentage of 21.6 of all patients registered CDSS score

at baseline above the cutt-off score for a major depressive episode

of 6, while 10.8% had CDSS score of 6 and 8.1% had a CDSS score of 5.

IDTS had greater scores in all these 15 patients with high CDSS val-

ues, comparative to the other, <4 CDSS score patients. Psychological

counseling and treatment adjustmentsweremade accordingly, and

after 3 months CDSS scores declined in all the subjects (

P

< 0.01).

Conclusions

Using a specific method for depression and suicide

risk in patients with schizophrenia and drug related disorder is very

useful for establishing a specific treatment approach and monitor-

ing plan.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.685

EW568

Insight, self-stigma and depressive

symptoms among patients with

schizophrenia

D. Vidovic

1 ,

, P. Brecic

2

, I. Jolic

3

, V. Jukic

3

1

Univeristy Psychiatric Hospital Vrapce, Department for

Psychophysiology, Zagreb, Croatia

2

University Psychiatric Hospital Vrapce, Department for Treatment

and Rehabilitation, Zagreb, Croatia

3

University Psychiatric Hospital Vrapce, Department for Forensic

Psychiatry, Zagreb, Croatia

Corresponding author.

Depressive symptoms are rather prevalent among patients with

schizophrenia and various factors can influence them. Insight and

self-stigma shows complex and contradictory relationship, both

are among most important features of schizophrenia with strong

impact on depressive symptoms. We wanted to test hypothesis

that preserved insight is related to depressive symptoms only

when self-stigma is also high. Our cross-sectional research com-

prised 149 patients with diagnosis of schizophrenia, both gender,

age span 25-45 years. Rating scales used were Calgary Depres-

sion Scale (CDS), Scale to assess Unawareness of Mental Disorder

(SUMD) and Internalized Stigma in Mental Illness (ISMI) which

are specifically designed for patients with schizophrenia. Major-

ity of patients were male (72%), single or separated (85%). Relation

between selfstigma and depressive symptoms was statistically

significant (

b

= 0.12, 95% CI = [0.06, 0.19],

= 0.32,

t

(135) = 3.89,

P

< 0.001) such as relationbetween selfstigma and insight (

b

= –0.01,

95% CI = [–0.02,–0.001],

= –0.17,

t

(135) = –2.20,

P

= 0.029). Post-

hoc analysis showed that among patients with extremely high

selfstigma (more than 90 centile), higher insight was related

to more depressive symptoms (b = –0.22, 95% CI = [–0.42,–0.02],

= –0.34,

t

= –2.23,

P

= 0.028). These results are important for tail-

oring specific antistigma programs for patients with high level of

insight in order to prevent deleterious impact of depressive symp-

toms on course of schizophrenia.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.686

EW569

Neurophysiological correlates of

negative symptom domains in

patients with schizophrenia

A. Vignapiano

1 ,

, V. Montefusco

1

, G.M. Plescia

1

, G. Di Lorenzo

2

,

C. Niol

u 2 , M.

Altamura

3 , D.

Marasco

3 , G.M

. Giordano

1 ,

A. Mucci

1 , S. G

alderisi

1

1

University of Naples SUN, Psychiatry, Naples, Italy

2

University of Rome “Tor Vergata”, Department of Systems Medicine,

Rome, Italy

3

University of Foggia, Department of Clinical and Experimental

Medicine- Psychiatry Unit, Foggia, Italy

Corresponding author.

Introduction

Negative symptoms have long been recognized as

a central feature of schizophrenia, which limit recovery, having a

strong negative impact on real-life functioning. External validators